Nanomerics

Nanoparticle-based drug delivery for developing precision medicines, to treat ophthalmology and central nervous system conditions.

Woman researcher examining samples under microscope with digital DNA on screen, working on biotechnology and genetic discovery

Nanomerics Ltd is a speciality pharmaceutical company based in London, UK.

The company was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Its proprietary proprietary Envelope Technology (MET) platform enhances and repurposes known drugs - getting more drug to the site of action, with improved activity and reduced side effects. 

It is based on world leading know-how and scientific leadership in polymer nanotechnology.

The Nanomerics journey so far: 

  • 2010: spinout founded as a collaboration between UCL, University of Glasgow and Strathclyde
  • 2024:
    • Molecular Envelope Technology (MET) validated across multiple drug classes
    • Winner of The King's Award for Enterprise: Innovation, and RSC Emerging Technologies Prize
  • 2025: OC134 Phase I clinical trial met all primary endpoints. OC134 and the MET platform were well tolerated in healthy volunteers (no adverse events of moderate or severe severity).
     

Team

Professor Dame Ijeoma Uchegbu

Co-founder and Chief Scientific Officer

Multi-award-winning nanotechnology scientist and lead inventor of the MET platform. Professor of Pharmaceutical Nanoscience, UCL. Board member, Wellcome Trust. President, Wolfson College Cambridge.

Dr. Adam Hajjar

Senior Business Manager

Dr Hajjar is primarily responsible for the identification, protection and commercialisation of technologies and IP developed at the UCL School of Pharmacy.

Adam is an experienced IP management and technology commercialisation professional, with a Life Sciences technical background, coupled with over 30 years’ experience gained through various commercial roles held across industry and academia. Prior to joining UCL Ventures, he was an Intellectual Asset & Commercialisation Specialist at BP Plc, where he led on IP strategy, portfolio management, and commercialisation activities across a broad range of technology and product areas, including oil and gas, bioenergy, renewable energy, and advanced materials. He has also held various senior commercial roles at the Cell and Gene Therapy Catapult, Plant Impact Plc, and Swiss Precision Diagnostics GmbH, providing relevant experience across pharmaceuticals, biotech, and diagnostics sectors.

He has also previously worked in a number of different technology transfer roles, supporting various London-based Universities (including King’s College London, University College London and the London School of Pharmacy) and their affiliated NHS Trusts in the protection and commercialisation on of a wide range of healthcare and pharmaceuticals related technologies and IP, mainly through patenting, licensing, and spin-out company related activities.

Adam holds a BSc in Microbiology from the University of Aberdeen, as well as a PhD in Biochemistry from the University of Kent.